Avricore Health Inc (AVCR) - Total Assets
Based on the latest financial reports, Avricore Health Inc (AVCR) holds total assets worth CA$584.37K CAD (≈ $422.72K USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Avricore Health Inc - Total Assets Trend (2000–2025)
This chart illustrates how Avricore Health Inc's total assets have evolved over time, based on quarterly financial data. Also see AVCR market cap for the company's overall valuation and market capitalisation.
Avricore Health Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Avricore Health Inc's total assets of CA$584.37K consist of 65.1% current assets and 35.0% non-current assets. Review AVCR current and long-term liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (CAD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CA$0.00 | 40.5% |
| Accounts Receivable | CA$11.88K | 2.1% |
| Inventory | CA$0.00 | 0.0% |
| Property, Plant & Equipment | CA$0.00 | 0.0% |
| Intangible Assets | CA$3.00 | 0.0% |
| Goodwill | CA$0.00 | 0.0% |
Asset Composition Trend (2000–2025)
This chart illustrates how Avricore Health Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See AVCR stock price and chart for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Avricore Health Inc's current assets represent 65.1% of total assets in 2025, an increase from 64.4% in 2000.
- Cash Position: Cash and equivalents constituted 40.5% of total assets in 2025, down from 62.0% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2000.
- Asset Diversification: The largest asset category is accounts receivable at 2.1% of total assets.
Avricore Health Inc Competitors by Total Assets
Key competitors of Avricore Health Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
GeneDx Holdings Corp.
NASDAQ:WGS
|
USA | $481.49 Million |
|
Shanghai Runda Med Tech Co
SHG:603108
|
China | CN¥13.79 Billion |
|
Shanghai Rendu Biotechnology Co. Ltd. A
SHG:688193
|
China | CN¥984.02 Million |
|
DIVA Laboratories Ltd
TWO:4153
|
Taiwan | NT$1.38 Billion |
|
Genoray Co. Ltd
KQ:122310
|
Korea | ₩131.23 Billion |
|
RHYTHM Biosciences Ltd
AU:RHY
|
Australia | AU$3.10 Million |
|
Check-Cap Ltd
F:7CC
|
Germany | €7.49 Million |
|
Sonic Healthcare Ltd
AU:SHL
|
Australia | AU$16.78 Billion |
Avricore Health Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.03 | 7.40 | 13.53 |
| Quick Ratio | 0.93 | 7.38 | 13.53 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CA$11.57K | CA$1.20 Million | CA$2.30 Million |
Avricore Health Inc - Advanced Valuation Insights
This section examines the relationship between Avricore Health Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 35.61 |
| Latest Market Cap to Assets Ratio | 9.74 |
| Asset Growth Rate (YoY) | -75.5% |
| Total Assets | CA$563.12K |
| Market Capitalization | $5.48 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Avricore Health Inc's assets at a significant premium (9.74x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Avricore Health Inc's assets decreased by 75.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Avricore Health Inc (2000–2025)
The table below shows the annual total assets of Avricore Health Inc from 2000 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CA$563.12K ≈ $407.36K |
-75.50% |
| 2024-12-31 | CA$2.30 Million ≈ $1.66 Million |
-9.44% |
| 2023-12-31 | CA$2.54 Million ≈ $1.84 Million |
-1.20% |
| 2022-12-31 | CA$2.57 Million ≈ $1.86 Million |
+12.61% |
| 2021-12-31 | CA$2.28 Million ≈ $1.65 Million |
+418.39% |
| 2020-12-31 | CA$440.09K ≈ $318.35K |
+111.18% |
| 2019-12-31 | CA$208.40K ≈ $150.75K |
-82.64% |
| 2018-12-31 | CA$1.20 Million ≈ $868.21K |
-58.62% |
| 2017-12-31 | CA$2.90 Million ≈ $2.10 Million |
+27.46% |
| 2016-12-31 | CA$2.28 Million ≈ $1.65 Million |
-34.86% |
| 2015-12-31 | CA$3.49 Million ≈ $2.53 Million |
-1.34% |
| 2014-12-31 | CA$3.54 Million ≈ $2.56 Million |
+331.56% |
| 2013-12-31 | CA$820.42K ≈ $593.48K |
+2.43% |
| 2012-12-31 | CA$800.99K ≈ $579.42K |
+3955.45% |
| 2011-12-31 | CA$19.75K ≈ $14.29K |
-89.63% |
| 2010-12-31 | CA$190.49K ≈ $137.80K |
-85.92% |
| 2009-12-31 | CA$1.35 Million ≈ $978.79K |
-24.07% |
| 2008-12-31 | CA$1.78 Million ≈ $1.29 Million |
-29.67% |
| 2007-12-31 | CA$2.53 Million ≈ $1.83 Million |
+196.66% |
| 2006-12-31 | CA$854.17K ≈ $617.89K |
+293.86% |
| 2005-12-31 | CA$216.87K ≈ $156.88K |
-27.92% |
| 2004-12-31 | CA$300.89K ≈ $217.66K |
-63.78% |
| 2003-12-31 | CA$830.76K ≈ $600.96K |
+189.93% |
| 2002-12-31 | CA$286.54K ≈ $207.28K |
+50.99% |
| 2001-12-31 | CA$189.77K ≈ $137.28K |
+125.97% |
| 2000-12-31 | CA$83.98K ≈ $60.75K |
-- |
About Avricore Health Inc
Avricore Health Inc. engages in the health data and point-of-care technologies businesses in Canada and the United Kingdom. It provides HealthTab, a turnkey point-of-care testing platform for pharmacies that can test up to 27 biomarkers on the spot for screening and managing chronic conditions, such as diabetes. The company was formerly known as Vanc Pharmaceuticals Inc. and changed its name to A… Read more